Project Grant R01EY033824

Award Date 9/30/22
Completion Date 8/31/26
Dollars Obligated $2.4M
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) will support research to investigate the role of retinal signaling pathways in the development of myopia, or nearsightedness. The $391,250 award to Emory University will fund a 5-year study to quantify changes in on and off retinal pathways in myopic eyes, determine how disrupting the balance between these pathways impacts myopia susceptibility, and evaluate the influence of ambient light levels on this...
This $148,568 Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research at Emory University to investigate the role of scleral fibroblasts in refractive development and myopia. The primary objectives are to: 1) Identify characteristics of scleral fibroblasts in mouse eyes that undergo normal refractive development versus those exposed to myopic stimuli, and 2) Determine the role of retinoic acid signaling in driving...
This federal Project Grant award of $494,418.00 from the National Eye Institute (CFDA 93.867 - Vision Research) will support research to investigate the role of the visual environment in the development of myopia, or nearsightedness. The key objectives are: Determine the anti-myopia effectiveness of different real-world visual scenes to understand how the visual environment impacts eye growth and refractive development. Develop improved "repeated low-level red light" therapies that...
The National Eye Institute (NEI) awarded a Project Grant (CFDA 93.867 Vision Research) worth $210,534 to Legacy Emanuel Hospital & Health Center in Portland, Oregon. The grant, which runs from September 1, 2024 to August 31, 2026, will fund research to investigate the cellular, molecular, and structural alterations in the optic nerve head associated with the development and progression of juvenile myopia using a tree shrew model. Key objectives of the project include assessing changes in...
The National Eye Institute (NEI) awarded a $433,125 federal Project Grant (CFDA 93.867 - Vision Research) to The Ohio State University to leverage data from the Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) study to address critical clinical questions in myopia control. The funded research aims to analyze axial length data to determine whom to treat and whether myopia control treatments are beneficial, assess the effects of time spent outdoors and sports...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $441,375.00 to The Regents of the University of California, Berkeley to explore pharmacological interventions for slowing the progression of myopia (nearsightedness) using a guinea pig animal model. The funded research will investigate the efficacy of topical treatments combining levodopa-carbidopa and atropine-levodopa-carbidopa in inhibiting defocus-induced myopia, and explore the underlying...
This $428,349 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports research by The Medical College of Wisconsin, Inc. to investigate the mechanisms controlling the development of retinal ganglion cells (RGCs). The key objectives are to: Examine the shared cis-regulatory elements and target genes of the transcription factors ATOH7, POU4F2, and ISL1 that are critical for RGC genesis. This will involve testing their spatial-temporal expression patterns in...
The federal Project Grant award R21EY036536 was provided by the National Eye Institute (CFDA 93.867 Vision Research program) to the University of Alabama at Birmingham (UAB) to conduct a pilot study on using amber light exposure to slow myopia progression and axial eye elongation in children. The $816,750 award will fund a 2-year study to determine the efficacy of having myopic children wear amber-tinted contact lenses for up to 4 hours per day. The study aims to test the hypothesis that...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research to understand the role of the signaling protein SMAD4 in regulating the extracellular matrix of the corneal stroma. The $243,000 grant, awarded on February 1, 2025, will be used by the University of Cincinnati to conduct two specific aims over 2 years: Rescue the progressive corneal stromal thinning phenotype observed in TBR1 knockout mice by targeting...
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $222,208 to The New England College of Optometry to investigate the effect of lens refractive index on measurements of the axial length of the human eye. The research aims to develop a novel, non-contact system that can simultaneously measure lens refractive index and axial length in vivo. This will allow for more accurate axial length measurements, which are crucial for research studies and...

MOLECULAR MECHANISMS OF EMMETROPIZATION AND EXPERIMENTAL MYOPIA AT SINGLE CELL RESOLUTION - PROJECT SUMMARY MORE THAN HALF OF THE WORLD'S POPULATION IS PROJECTED TO BE MYOPIC (NEARSIGHTED) BY 2050, SIGNIFICANTLY RAISING THE RISK OF ASSOCIATED VISION-THREATENING CONDITIONS INCLUDING RETINAL DETACHMENT, MACULOPATHY, AND GLAUCOMA. DESPITE THE DEVELOPMENT OF SEVERAL EVIDENCE-BASED TREATMENTS TO MANAGE MYOPIA PROGRESSION, THE PREVALENCE AND COMPLICATION RATES CONTINUE TO RISE, AND TREATMENT EFFICACY IS ONLY PARTIAL. EXPERIMENTAL AND CLINICAL RESEARCH SHOWS THAT COMPLEX GENE-ENVIRONMENT INTERACTIONS ARE INVOLVED IN THE CONTROL OF THE POST-NATAL GROWTH OF THE EYE AND ITS OPTICAL DEVELOPMENT, INCLUDING MYOPIA ONSET AND PROGRESSION. RESEARCH USING ANIMAL MODELS HAS CONFIRMED THAT VISUAL EXPERIENCE AND RETINAL DEFOCUS CONTROL EYE GROWTH AND THE DEVELOPMENT OF REFRACTIVE STATE THROUGH THE PROCESS OF EMMETROPIZATION. WHILE PROGRESS HAS BEEN MADE UNCOVERING SOME OF THE BIOCHEMICAL FACTORS ASSOCIATED WITH EXPERIMENTAL MYOPIA, VERY LITTLE IS KNOWN ABOUT THE UNDERLYING CELLULAR AND MOLECULAR MECHANISMS CONTROLLING EMMETROPIZATION AND MYOPIA DEVELOPMENT. THIS MULTI-PI CONSORTIUM GRANT BRINGS TOGETHER EXPERIENCED RESEARCHERS AND THEIR ESTABLISHED EXPERIMENTAL NON- HUMAN PRIMATE MODEL OF EMMETROPIZATION AND MYOPIA WITH AN INTERNATIONALLY RECOGNIZED OCULAR GENOMICS RESEARCH CENTER TO PERFORM A MAJOR INVESTIGATION OF THE RETINAL, RPE, CHOROIDAL, AND SCLERAL BIOLOGY OF POST-NATAL EYE GROWTH AND MYOPIA DEVELOPMENT. THIS PROJECT EXAMINES THE FUNCTIONAL GENOMICS AND GENE-ENVIRONMENT INTERACTIONS IN THE REFRACTIVE DEVELOPMENT OF THE PRIMATE EYE AND WILL IDENTIFY MOLECULAR MECHANISMS INVOLVED IN THE DEVELOPMENT OF MYOPIA USING SINGLE CELL AND BULK TRANSCRIPTOMICS, EPIGENOMICS, AND PROTEOMICS. THE INVESTIGATORS WILL IDENTIFY AND CONFIRM, USING ESTABLISHED BIOINFORMATIC APPROACHES, THE MAIN COMPONENTS OF KEY REGULATORY PATHWAYS UNDERLYING EMMETROPIZATION AND MYOPIA DEVELOPMENT. THESE STUDIES WILL PROVIDE DIRECT EVIDENCE AND A MORE COMPLETE UNDERSTANDING OF THE MECHANISMS OF VISUALLY REGULATED EYE GROWTH AND MYOPIA AND WILL PROVIDE THE LARGEST AND MOST COMPREHENSIVE SHARED RESOURCE OF CELLULAR AND MOLECULAR TARGETS TO DATE HELPING DEVELOP NEW THERAPIES TO CONTROL EYE GROWTH AND MANAGE REFRACTIVE ERRORS. THIS INVESTIGATION MEETS THREE OF THE FOUR NEI OBJECTIVES FOR MYOPIA RESEARCH: TO INVESTIGATE THE BIOCHEMICAL PATHWAYS THAT REGULATE EYE GROWTH; TO IDENTIFY GENES THAT CONTRIBUTE TO THE DEVELOPMENT OF REFRACTIVE ERRORS; AND WILL HELP DEVELOP NEW TECHNOLOGIES FOR ASSESSING OR TREATING REFRACTIVE ERRORS.

Posted 9/20/22, 12:00 AM